Study drug HF158K1 for HER2-positive advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This Phase 1 trial tests HF158K1 in people with advanced solid tumors that have HER2 protein. It aims to see if the drug can be given safely and learn how it works in people whose cancer shows HER2 on tumor testing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old, and you choose to join by signing consent.
- Your cancer is advanced (metastatic or cannot be removed) and has HER2 on tumor testing (HER2 IHC 1+, 2+, or 3+).
- Your general condition is good (ECOG 0 to 1), and doctors expect you may live at least 6 months.
- Your scans show at least one measurable tumor spot, and you have enough blood and organ function (blood counts, liver, kidney, and a heart pumping strength of LVEF ≥ 50%).
- You can use effective birth control, if that applies to you; you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug for people with advanced or metastatic HER2-positive solid tumors. The drug is designed to target cancer cells with HER2 and may slow tumor growth.
This study tests a new drug called KM257 for people with advanced solid tumors that have a high level of a protein called HER2. The drug is given as an infusion and is designed to target cancer cells with this protein, potentially slowing or stopping tumor growth.
This Phase 1 trial tests IKS014 to see how safe it is and how well it works in advanced solid tumors that have HER2. You may be eligible if your tumor is HER2-positive (including certain “low HER2” types) and your body’s blood counts and organ function are strong enough.
This study tests different treatments tailored to your cancer's biology. It aims to find which therapy might work best for you, potentially improving outcomes. You'd receive one of the study drugs, with close monitoring and support.
This trial tests a new drug, HF50, in people with advanced solid tumors that are HER-2 positive or have low HER-2 levels. It may be an option if standard treatments have stopped working or are not tolerated.
This Phase 1 trial tests HS-20089 in people with advanced solid cancers that have limited standard treatment options. It focuses on safety and early signs of whether the drug can shrink tumors or control them.
Hear when a new Solid Tumors, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.